Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhNGF eye drops for retinitis pigmentosa-associated cystoid macular edema
2014-000385-22Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- May 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of cenegermin in retinitis pigmentosa (RP) and cystoid macular edema (CME) (2 arms), sponsored by IRCCS Ospedale San Raffaele. Primary endpoints: Effect on macular thickness and Composite treatment success. Started May 2014; status: completed.
02
Drugs
cenegermin
03
Conditions
retinitis pigmentosa (RP)cystoid macular edema (CME)
Beyond the preview
Go deeper on 2014-000385-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000385-22.